Symptomatic cases of COVID-19 dropped 94 percent after two doses of the Pfizer vaccine, according to a new study.
Israel’s largest healthcare provider, Clalit, looked at data from more than 600,000 people in what is the country’s largest study to date.
The study also found that people were 92 percent less likely to develop serious illness from the virus with the vaccinations.
“It shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world one week after the second dose, just as it turned out to be in the clinical trial,” said Ran Balicer, Clalit’s chief innovation officer.
The shot becomes even more effective two or more weeks after the second dose, Balicer said.
Researchers at the Weizmann Institute of Science also reported on Sunday that the number of hospitalizations and serious illness among Israelis 55 years of age or older has decreased significantly for the first time.
The first age group to be vaccinated in the country were people 60 years of age and older.
With pole wires